Supply Chain Intelligence

C4 Therapeutics, Inc. Supply Chain

CCCC supply chain intelligence for C4 Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

CCCC ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

5Suppliers
4Customers
3Debt Items
20Related Chains

C4 Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
PFE Pfizer Inc. 92% Pfizer supplying elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody, to C4T for the Phase 1b trial Dexamethasone (dex)
PFE Pfizer Inc. 92% Reciprocal relationship from PFE graph: Reciprocal relationship from CCCC graph: Pfizer supplying elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody, to C4T for the…
BETTA-PHARMA BETTA-PHARMA 90% Betta Pharma is responsible for all development, regulatory approval, manufacturing and commercialization costs in Greater China
BETTA-INVESTMENT-HONG-KONG-LIMITED BETTA-INVESTMENT-HONG-KONG-LIMITED 80% Betta Investment agreed to purchase 5,567,928 shares of the Company's common stock
GLUE Monte Rosa Therapeutics, Inc. 72% Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of t…

C4 Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
BETTA-PHARMACEUTICALS BETTA-PHARMACEUTICALS 90% License and collaboration agreement with Betta Pharmaceuticals for development and commercialization in Greater China
ROCHE ROCHE 85% the Company and Roche agreed to collaborate in the research, development, manufacture and commercialization of target-binding degrader medicines
GLUE Monte Rosa Therapeutics, Inc. 72% Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of t…
KYMR Kymera Therapeutics, Inc. 72% Reciprocal relationship from KYMR graph: Reciprocal relationship from CCCC graph: Reciprocal relationship from KYMR graph: hese manufacturers on a purchase order basis and do not have long-term suppl…

C4 Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
CCCC-DEBT-8517 Xbrl Convertible 90% xbrl convertible detail from xbrl 2020-12-31.
CCCC-DEBT-8516 Warrants outstanding: 8.86 90% xbrl warrant detail from xbrl 2026-03-31.
CCCC-DEBT Debt stack $60.0M 90% Market cache reports total debt of $60.0M.

C4 Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for C4 Therapeutics, Inc..

C4 Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
CCCC-OWNER-MORGAN-STANLEY MORGAN STANLEY 90% 13F overlay lists MORGAN STANLEY as top holder; 125 tracked holders.

C4 Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
NRIX Nurix Therapeutics, Inc. 100.00 1 ['receiving']
APRE Aprea Therapeutics, Inc. 100.00 2
IDYA IDEAYA Biosciences, Inc. 100.00 2
TNXP Tonix Pharmaceuticals Holding Corp. 100.00 2
OLMA Olema Pharmaceuticals, Inc. 100.00 2
NVS Novartis AG 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
DRTS Alpha Tau Medical Ltd. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
BCAX Bicara Therapeutics Inc. 100.00 2
MGNX MacroGenics, Inc. 100.00 2
CPMV Mosaic ImmunoEngineering, Inc. 100.00 2
DEO Diageo plc 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
GILD Gilead Sciences, Inc. 100.00 2
CRIS Curis, Inc. 100.00 2
ARGX argenx SE 100.00 2
View CCCC supply chain intel →

Explore the full interactive supply chain map for C4 Therapeutics, Inc..

Open CCCC supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map